AzTrials
AzTrials

Arthritis, RheumatoidPhase 2NCT00550446

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

A Phase 2 study testing Adalimumab, CP-690-550 and CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 63 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Rheumatoid
What is being tested?
Adalimumab, CP-690-550 and CP-690,550
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
386 participants
Where
63 sitesin 15 countries
Study dates
Sep 2007to Jan 2009
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must have active rheumatoid arthritis
  • Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)
  • Subjects must not be currently taking any DMARD other than an antimalarial

Who cannot join

  • Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety.
  • Subjects who previously received adalimumab (Humira®) therapy for any reason.
  • Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis

Trial locations and contacts

63 sites in 15 countries.

63 sites in 15 countries

United States22 sites
  • Pfizer Investigational Site

    Cedar Rapids, Iowa, 52401-2112

  • Pfizer Investigational Site

    Dallas, Texas, 75235

  • Pfizer Investigational Site

    Dayton, Ohio, 45408

  • Pfizer Investigational Site

    Duncansville, Pennsylvania, 16635

  • Pfizer Investigational Site

    Hickory, North Carolina, 28601

  • Pfizer Investigational Site

    Hickory, North Carolina, 28602

  • Pfizer Investigational Site

    Knoxville, Tennessee, 37909-1600

  • Pfizer Investigational Site

    Little Rock, Arkansas, 72205

  • Pfizer Investigational Site

    Mesa, Arizona, 85208

  • Pfizer Investigational Site

    Mesquite, Texas, 75150

  • Pfizer Investigational Site

    Morton Grove, Illinois, 60053

  • Pfizer Investigational Site

    New Orleans, Louisiana, 70115

  • Pfizer Investigational Site

    Northridge, California, 91325

  • Pfizer Investigational Site

    Orlando, Florida, 32804

  • Pfizer Investigational Site

    Palo Alto, California, 94304

  • Pfizer Investigational Site

    Rockford, Illinois, 61107

  • Pfizer Investigational Site

    Stanford, California, 94305

  • Pfizer Investigational Site

    Tampa, Florida, 33614

  • Pfizer Investigational Site

    Tarzana, California, 91356

  • Pfizer Investigational Site

    Upland, California, 91786

  • Pfizer Investigational Site

    Wichita, Kansas, 67203

  • Pfizer Investigational Site

    Wichita, Kansas, 67208

Other trials in United States

Czechia5 sites
  • Pfizer Investigational Site

    Brno, 656 91

  • Pfizer Investigational Site

    Prague, 128 50

  • Pfizer Investigational Site

    Prague, 140 59

  • Pfizer Investigational Site

    Praha 11 - Chodov, 148 00

  • Pfizer Investigational Site

    Zlín, 760 01

Other trials in Czechia

Ukraine5 sites
  • Pfizer Investigational Site

    Kharkiv, 61000

  • Pfizer Investigational Site

    Kyiv, 04114

  • Pfizer Investigational Site

    Lviv, 79011

  • Pfizer Investigational Site

    Vinnitsa, 21018

  • Pfizer Investigational Site

    Zaporizhzhya, 69118

Other trials in Ukraine

Bulgaria4 sites
  • Pfizer Investigational Site

    Pleven, 5800

  • Pfizer Investigational Site

    Sofia, 1612

  • Pfizer Investigational Site

    Sofia, 1709

  • Pfizer Investigational Site

    Sofia

Other trials in Bulgaria

Germany4 sites
  • Pfizer Investigational Site

    Dresden, 01067

  • Pfizer Investigational Site

    Hamburg, 22081

  • Pfizer Investigational Site

    Hildesheim, 31134

  • Pfizer Investigational Site

    Leipzig, 04103

Other trials in Germany

Mexico4 sites
  • Pfizer Investigational Site

    Cuernavaca, Morelos, 62270

  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44650

  • Pfizer Investigational Site

    Metepec, State of Mexico, 52140

  • Pfizer Investigational Site

    México, D.f., 06100

Other trials in Mexico

Chile3 sites
  • Pfizer Investigational Site

    Providencia, Santiago, RM, 7530206

  • Pfizer Investigational Site

    Santiago, RM, 8331030

  • Pfizer Investigational Site

    Santiago, RM, 8360156

Other trials in Chile

Romania3 sites
  • Pfizer Investigational Site

    Bucharest, 011172

  • Pfizer Investigational Site

    Constanța, Constanța County, 900591

  • Pfizer Investigational Site

    Iași, Iaşi, 700661

Other trials in Romania

Brazil2 sites
  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, 90035-903

  • Pfizer Investigational Site

    São Paulo, São Paulo, 01323-903

Other trials in Brazil

Croatia2 sites
  • Pfizer Investigational Site

    Split, 21000

  • Pfizer Investigational Site

    Zagreb, 10000

Other trials in Croatia

Greece2 sites
  • Pfizer Investigational Site

    Goudi, Athens, 11527

  • Pfizer Investigational Site

    Thessaloniki, 54 636

Other trials in Greece

Italy2 sites
  • Pfizer Investigational Site

    Florence, 50139

  • Pfizer Investigational Site

    Genova, 16132

Other trials in Italy

Slovakia2 sites
  • Pfizer Investigational Site

    Piešťany, 921 12

  • Pfizer Investigational Site

    Žilina, 012 07

Other trials in Slovakia

South Korea2 sites
  • Pfizer Investigational Site

    Seoul, 110-744

  • Pfizer Investigational Site

    Seoul, 133-792

Other trials in South Korea

Hungary1 site
  • Pfizer Investigational Site

    Szolnok, H-5000

Other trials in Hungary

About this study

Official title: A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)

Being tested
Adalimumab, CP-690-550, CP-690,550, Placebo
Keywords
Janus Kinase 3 Clinical Trial
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AdalimumabDrug

    40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.

  • CP-690-550Drug

    15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

  • CP-690-550Drug

    10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

  • CP-690-550Drug

    5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)

  • CP-690,550Drug

    3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)

  • CP-690,550Drug

    1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)

  • PlaceboDrug

    Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)

Study groups in NCT00550446
Study groupRoleWhat they receive
1Active comparatorNot described
Receives: Drug: Adalimumab
2ExperimentalNot described
Receives: Drug: CP-690-550
3ExperimentalNot described
Receives: Drug: CP-690-550
4ExperimentalNot described
Receives: Drug: CP-690-550
5ExperimentalNot described
Receives: Drug: CP-690,550
6ExperimentalNot described
Receives: Drug: CP-690,550
7Placebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12

    ACR20 response: greater than or equal to (>=) 20 % improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).

    Measured: Week 12

Secondary outcomes (30)
  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

    ACR20 response: 20% improvement in TJC; >=20% improvement in SJC; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Week 2, 4, 6, 8, 10, 16, 20 and 24/Early Termination (ET)

  2. Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response

    ACR50 response: >= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  3. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

    ACR70 response: >= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  4. Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response

    ACR90 response: >= 90% improvement in TJC or SJC and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  5. Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve

    ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. Area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.

    Measured: Baseline up to Week 2, 4, 6, 8, 10, 12

  6. Tender Joint Count (TJC)

    Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  7. Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET

    Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  8. Swollen Joint Counts (SJC)

    Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  9. Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24

    Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling = 1. A negative value in change from baseline indicated an improvement.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  10. Patient Assessment of Arthritis Pain

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  11. Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

  12. Patient Global Assessment (PtGA) of Arthritis Pain

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

    Measured: Baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  13. Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  14. Physician Global Assessment (PGA) of Arthritis

    Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  15. Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  16. C-Reactive Protein (CRP)

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  17. Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  18. Health Assessment Questionnaire-Disability Index (HAQ-DI)

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  19. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  20. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (<=) 3.2 implied low disease activity and greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and less than (<) 2.6 = remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET

  21. Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and > 3.2 to 5.1 implied moderate to high disease activity, and < 2.6 = remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET

  22. Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) <= 3.2 implies low disease activity and > 3.2 to 5.1 implies moderate to high disease activity, and < 2.6 = remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET

  23. Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET

    DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR [mm/hour] and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) <= 3.2 implies low disease activity and > 3.2 to 5.1 implies moderate to high disease activity, and < 2.6 = remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  24. Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR)

    Disease improvement was classified as good, moderate, and none based on improvement in DAS28-4 (ESR) from baseline and present DAS28-4 (ESR) score. Good: an improvement from baseline of >1.2 and a present score of <=3.2; none: an improvement of <=0.6 or >0.6 to <=1.2 with a present score of >5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET

  25. Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP)

    CRP value less than or equal to upper limit of normal (ULN) implied disease remission (ULN=4.9 mg/L).

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET

  26. Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)

    DAS28-3 (CRP) defined remission was classified as a score of <2.6.

    Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET

  27. 36-Item Short-Form Health Survey (SF-36)

    SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline, Week 12, 24/ ET

  28. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET

    SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline, Week 12, 24/ ET

  29. Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Week 12, 24/ ET

  30. Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Week 12, 24/ ET

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2007 (estimated)
  2. Study startSep 2007
  3. Primary completionJan 2009
  4. Study completionJan 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
386 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00550446
Sponsor's protocol ID
A3921035
Status last verified
Nov 2012
First submitted
25 Oct 2007
Last updated
3 Jan 2013
Data monitoring committee
No

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.

    PubMed 37453736
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

    PubMed 34870800
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.

    PubMed 33127856
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.

    PubMed 32816215
  • Suzuki M, Shoji S, Miyoshi S, Krishnaswami S. Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients. J Clin Pharmacol. 2020 Feb;60(2):198-208. doi: 10.1002/jcph.1514. Epub 2019 Sep 12.

    PubMed 31512746
  • Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.

    PubMed 28941219
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

    PubMed 28143815
  • Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016 May-Jun;34(3):430-42. Epub 2016 Apr 28.

    PubMed 27156561

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Adalimumab, CP-690-550 and CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 63 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 63 sites in United States, Czechia, Ukraine, Bulgaria, Germany and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00550446, which also lists 18 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in